Some studies have reported that HDAC6 inhibitors can enhance the activity of Taxol in ARID1A-null ovarian cancer cells [23] and tumor models [19], partly due to the disruption of microtubule dynamics. Here, ARID1A is linked to ovarian carcinoma.